{
    "clinical_study": {
        "@rank": "119574", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Evaluate the effects of androgen suppression with leuprolide and androgen replacement\n      with testosterone enanthate on muscle strength in men with Kennedy's disease or other motor\n      neuron disease."
        }, 
        "brief_title": "Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease", 
        "condition": [
            "Spinal Muscular Atrophy", 
            "Amyotrophic Lateral Sclerosis", 
            "Spinobulbar Muscular Atrophy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Amyotrophic Lateral Sclerosis", 
                "Muscular Atrophy", 
                "Muscular Atrophy, Spinal", 
                "Sclerosis", 
                "Motor Neuron Disease", 
                "Atrophy", 
                "Muscular Disorders, Atrophic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      All patients receive androgen suppression with leuprolide acetate injections every 4 weeks\n      for 6 months, plus hormone replacement therapy with testosterone enanthate injections every\n      week for 24 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Men aged 18 and over with motor neuron disease, i.e.:\n\n          -  X-linked spinal and bulbar muscular atrophy (Kennedy's disease)\n\n          -  Confirmed by androgen receptor, exon-1 mutation genotype\n\n          -  Amyotrophic lateral sclerosis\n\n          -  Spinal muscular atrophy\n\n        Significant muscle weakness on manual muscle testing\n\n        No prisoners\n\n        No mental disability"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004771", 
            "org_study_id": "199/11792", 
            "secondary_id": "OSU-92H0325"
        }, 
        "intervention": [
            {
                "intervention_name": "leuprolide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "testosterone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone", 
                "Leuprolide"
            ]
        }, 
        "keyword": [
            "amyotrophic lateral sclerosis", 
            "motor neuron disease", 
            "neurologic and psychiatric disorders", 
            "rare disease", 
            "spinal and bulbar muscular atrophy", 
            "spinal muscular atrophy", 
            "Kennedy's Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Ohio State University", 
            "last_name": "Jerry R. Mendell", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004771"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Ohio State University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 1992", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2001"
    }, 
    "geocoordinates": {}
}